Conference abstract · 19 Jun 2017
Conference abstractPublished 22 May 2017
Non-communicable disease comorbidities and treatment outcomes among people living with human immunodeficiency virus on highly active anti-retroviral therapy at Jimma University Specialized Hospital, South West Ethiopia: Nested case-control study
Jimma University, Ethiopia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: The life expectancy of people living with human immunodeficiency virus (HIV) has dramatically improved with the much increased access to antiretroviral therapy. Consequently, a larger number of people living with HIV are living longer and facing the increased burden of non-communicable diseases. Objective: To assess effect of chronic diseases comorbidities and determinants of treatment outcomes among HIV infected patients on highly active anti-retroviral therapy at Jimma University Specialized Hospital. Methods: A nested case-control study was conducted among people living with HIV at Jimma University Specialized Hospital from February 20 to August 20, 2016. Patient specific data was collected using structured data collection tool to identify relevant information and also patient reported outcome quality of life-HIV (PROQOL-HIV) scale was used to assess health related quality of life of patient. Data was analyzed using statistical package for Social Science version 20.0. Logistic and linear regressions were done to identify factor associated to outcomes. Statistical significance was considered at p-value <0.05. Results: A total of 160 participants, 80 cases and 80 controls were included in the analysis. Among cases; hypertension accounts 13.8%, followed by diabetes (11.9%) and about 12.5% had multimorbidity. At baseline, the mean (Ã?±SD) age of cases was 42.32Ã?±10.69 years, whereas it was 38.41Ã?±8.23 years among controls. The median baseline CD4+ cell count was 184.50 cells/Ã?¼L (IQR: 98.50-284.00 cells/Ã?¼L) for cases and 177.0 cells/Ã?¼L (IQR: 103.75-257.25 cells/Ã?¼L) for controls. Post 6-months of highly active anti-retroviral therapy initiation, immunologic failure was 28.80% among cases and it was 16.25% among controls. An average increase of CD4+ cell count was 6.4 cells per Ã?¼L per month among cases and 7.6 cells per Ã?¼L per month among controls. The meanÃ?±SD score of health related quality of life among cases was 57.39Ã?±6.89, 73.52Ã?±13.22, 64.15Ã?±9.03, 81.37Ã?±8.31 and it was 71.74Ã?±21.64, 76.48Ã?±11.88, 67.25Ã?±9.67, 81.53Ã?±8.08 among controls in physical health and symptoms, health concerns and mental distress, social and intimate relationships, treatment-related impact dimension respectively. Male sex [AOR, 3.51; 95% CI, 1.496 to 8.24; p=0.004], smoking history [AOR, 2.81; 95% CI, 1.072, to 7.342; p=0.036] and comorbidity with noncommunicable chronic diseases [AOR 3.99; 95% CI, 1.604 to 9.916; p=0.003)] are independent predictors of immunologic failure. Conclusions & Recommendations: Chronic non-communicable diseases have negative effects on the kinetics of CD4+ cell count and also have negative impact on quality of life among HIV-infected patients who initiated antiretroviral therapy. So integration of chronic non-communicable disease-HIV collaborative activities will strengthen battle to control double burden of chronic illnesses.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 2018
Treatment outcomes of people living with Human Immunodeficiency Virus on highly active anti-retroviral therapy in Ethiopia: Does non-communicable disease(s) co-morbidities matters?
Research article · 2023
Medium-Long Term Impacts of Anti-retroviral Drugs on Arterial Blood Pressure in People Living with HIV in Malawi
Conference abstract · 13 Nov 2017
Exploring Underpinnings Weighing Down the Phenomenon of Adherence to Anti-Retroviral Drugs (ARVs) among the People Living With HIV/AIDS (PLWHA) in South Africa and Botswana: A Literature Review
Short communication · 24 Sep 2020
HIV positive sero-status disclosure and its associated factors among people living with HIV /AIDS following ART clinic in Jimma University Specialized Hospital, Southwest Ethiopia: a facility- based cross-sectional study
More from this journal
The newest in Journal of Clinical Trials.
Case report · 10 Aug 2026
Tuberculosis Associated Spondylolisthesis and Radiculopathy
Short communication · 31 Jul 2026
Understanding Bioavailability as a Key Element in Effective Therapeutic Delivery
Research article · 14 Jun 2026
Ensuring Rights and Dignity in Ethical Practices of Clinical Studies with Vulnerable Group and Safeguarding Vulnerable Group Act (2006)
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical Trials
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Tsegaye Melaku Kebede”
- BylineArticles whose byline prints “Girma Mamo”
- BylineArticles whose byline prints “Legese Chelkeba”
- BylineArticles whose byline prints “Tesfahun Chanie”

